Letter to the editor: Neutralizing antibodies for the treatment of COVID-19 被引量：4

导出

摘要 To the Editor:Coronavirus disease 2019(COVID-19)is a global epidemic caused by the infection of severe acute respiratory coronavirus 2(SARS-Co V-2)and its mortality rate was up to 20 times higher than that of influenza.The virus is infectious,strange and variable.

作者 Zeqi Zhou Xiangbin Wang Yankai Fu Xiqing Zhang Changxiao Liu

机构地区 Dynamiker Biotechnology Sub-Center Beijing Antai Zhiyuan Technology Co. State Key Laboratory of Drug Delivery Technology and Pharmacokinetics

出处《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2021年第1期304-307,共4页 药学学报（英文版）

关键词 SARS-CoV-2 Neutralizing antibody therapy COVID-19

分类号 R563.1 [医药卫生—呼吸系统]

引文网络
相关文献

同被引文献33

1张超,陈姝冰,张洁,郭颖.浅析注册用于新冠肺炎治疗的临床试验药物[J].药学学报,2020,55(3):355-365. 被引量：27
2Haiyan Yan,Jing Sun,Kun Wang,Huiqiang Wang,Shuo Wu,Linlin Bao,Weiqing He,Dong Wang,Airu Zhu,Tian Zhang,Rongmei Gao,Biao Dong,Jianrui Li,Lu Yang,Ming Zhong,Qi Lv,Feifei Qin,Zhen Zhuang,Xiaofang Huang,Xinyi Yang,Yuhuan Li,Yongsheng Che,Jiandong Jiang.Repurposing carrimycin as an antiviral agent against human coronaviruses,including the currently pandemic SARS-CoV-2[J].Acta Pharmaceutica Sinica B,2021,11(9):2850-2858. 被引量：15
3Xiaopan Gao,Bo Qin,Pu Chen,Kaixiang Zhu,Pengjiao Hou,Justyna Aleksandra Wojdyla,Meitian Wang,Sheng Cui.Crystal structure of SARS-CoV-2 papain-like protease[J].Acta Pharmaceutica Sinica B,2021,11(1):237-245. 被引量：11
4Xiaofei Chen,Yunlong Wu,Chun Chen,Yanqiu Gu,Chunyan Zhu,Suping Wang,Jiayun Chen,Lei Zhang,Lei Lv,Guoqing Zhang,Yongfang Yuan,Yifeng Chai,Mingshe Zhu,Caisheng Wu.Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening[J].Acta Pharmaceutica Sinica B,2021,11(1):222-236. 被引量：48
5Liqiang Ni,Lili Chen,Xia Huang,Chouping Han,Jianrong Xu,Hong Zhang,Xin Luan,Yongfang Zhao,Jianguang Xu,Weian Yuan,Hongzhuan Chen.Combating COVID-19 with integrated traditional Chinese and Western medicine in China[J].Acta Pharmaceutica Sinica B,2020,10(7):1149-1162. 被引量：33
6刘千勇,王晓良.新型冠状病毒(2019-nCoV)的靶向药物研究策略[J].药学学报,2020,55(2):181-188. 被引量：43
7Xin Liu,Xiu-jie Wang.Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines[J].Journal of Genetics and Genomics,2020,47(2):119-121. 被引量：18
8刘青(译),刘莉(审校),Lu R,Zhao X,Li J,Niu P,Yang B,Wu H,Wang W,Song H,Huang B,Zhu N,Bi Y,Ma X,Zhan F,Wang L,Hu T,Zhou H,Hu Z,Zhou W,Zhao L,Chen J,Meng Y,Wang J,Lin Y,Yuan J,Xie Z,Ma J,Liu WJ,Wang D,Xu W,Holmes EC,Gao GF,Wu G,Chen W,Shi W,Tan W.2019新型冠状病毒基因组特征和流行病学:病毒起源和受体结合的意义[J].中华高血压杂志,2020,28(3):212-212. 被引量：549
9Xin Zou,Ke Chen,Jiawei Zou,Peiyi Han,Jie Hao,Zeguang Han.Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection[J].Frontiers of Medicine,2020,14(2):185-192. 被引量：210
10Manli Wang,Ruiyuan Cao,Leike Zhang,Xinglou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J].Cell Research,2020,30(3):269-271. 被引量：609

引证文献4

1朱文祥.香港特区大学的化学教育[J].大学化学,2000,15(2):56-62.
2Zeqi Zhou,Xiangbin Wang,Xiqing Zhang,Yuan Zhang,Yankai Fu,Zhixian Wang,Yan Su,He Wang,Meng Xiao,Changxiao Liu.Significance of neutralizing antibodies in COVID-19 therapy:progress and prospect[J].Journal of Chinese Pharmaceutical Sciences,2021,30(2):87-106. 被引量：2
3佟可心,蔡孟华,何维,张建民.针对SARS-CoV2不同突变株广谱特异性中和抗体的筛选与鉴定[J].基础医学与临床,2022,42(5):752-757.
4林梨萍,唐飞,许瑞安,崔秀灵.抗COVID-19药物的研究进展[J].药学学报,2023,58(1):39-51. 被引量：2

二级引证文献4

1刘腾飞,魏慧慧,张缭云,卫飞燕,王蓉,袁永佳,于德顺.新型冠状病毒肺炎康复者血清中和抗体水平的随访研究[J].中华传染病杂志,2022,40(11):679-681.
2邬林枫,陈婷婷,王皓飚,刘衡,李彤,王立林,许晓绚,曾劲峰.新冠疫情防控不同时期深圳地区无偿献血人群新冠病毒抗体检测结果[J].中国输血杂志,2023,36(12):1098-1101.
3梅钰恒,李佳玉,宋丹青,彭宗根,李迎红.石蒜碱类衍生物的合成与抗SARS-CoV-2的活性和作用机制研究[J].药学学报,2024,59(2):395-403.
4周雯雯,尤宝庆,郑怡凡,司书毅,李妍,张晶.组织蛋白酶L小分子抑制剂的抗SARS-CoV-2活性研究[J].药学学报,2024,59(3):600-607. 被引量：1

1Liang Guo,Wenwen Bi,Xinling Wang,Wei Xu,Renhong Yan,Yuanyuan Zhang,Kai Zhao,Yaning Li,Mingfeng Zhang,Xia Cai,Shibo Jiang,Youhua Xie,Qiang Zhou,Lu Lu,Bobo Dang.Engineered trimeric ACE2 binds viral spike protein and locks it in"Thfee-up"conformation to potently inhibit SARS-CoV-2 infection[J].Cell Research,2021,31(1):98-100. 被引量：7
2Kun YANG,Ming-you XING,Ling-yu JIANG,Yan-ping CAI,Li-li YANG,Na-na XIE,Jia CHEN,Wen-xia WANG,Li WANG,Ji-ling ZHU,Ding-yu ZHANG,Qiu-rong RUAN,Jian-xin SONG.Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19[J].Current Medical Science,2021,41(1):39-45. 被引量：2
3Imre Berger,Christiane Schaffitzel.The SARS-CoV-2 spike protein: balancing stability and infectivity[J].Cell Research,2020,30(12):1059-1060. 被引量：1
4Alina Baum.REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters[J].四川生理科学杂志,2021,43(1):118-118.
5海南医学编辑部(翻译/整理).抗体亲和力决定记忆B细胞和生发中心B细胞的命运[J].海南医学,2021,32(5).
6Hai Zou,Shengqing Li.ECMO/CRRT Combined Support in the Treatment of Critically Ill SARS-CoV-2 Pneumonia Patients[J].Cardiovascular Innovations and Applications,2021(1):183-192.
7Junsen Chen,Rui Huang,Yiwen Nie,Xinyue Wen,Ying Wu.Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19[J].Virologica Sinica,2020,35(6):713-724. 被引量：1
8Yu-Qiang Lu,Lin FU,Yu-Qi Hao,Hui Ding,Zhao-Lin Shi,Ru-Ying Li,Guo-Cheng Zhang.A study on the rule of Chinese medicine use against influenza virus based on data mining[J].Medical Data Mining,2021,4(1):28-37. 被引量：1
9Xingyu Wang,Kun Huang,Haini Jiang,Lijuan Hua,Weiwei Yu,Dan Ding,Ke Wang,Xiaopan Li,Zhong Zou,Meilin Jin,Shuyun Xu.Long-Term Existence of SARS-CoV-2 in COVID-19 Patients:Host Immunity,Viral Virulence,and Transmissibility[J].Virologica Sinica,2020,35(6):793-802. 被引量：5
10Balamurugan Shanmugaraj,Waranyoo Phoolcharoen.Addressing demand for recombinant biopharmaceuticals in the COVID-19 era[J].Asian Pacific Journal of Tropical Medicine,2021,14(2):49-51.

Acta Pharmaceutica Sinica B

2021年第1期

浏览历史

内容加载中请稍等...

Letter to the editor: Neutralizing antibodies for the treatment of COVID-19 被引量：4

同被引文献33

引证文献4

二级引证文献4

相关作者

相关机构

相关主题

浏览历史